Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2

Molecular Pharmacology

Volumn 68, Issue 2, 2005, Pages 393-402

  Mathiesen, Jesper Mosolff ^a   Ulven, Trond ^a   Martini, Lene ^a,c   Gerlach, Lars Ole ^a   Heinemann, Akos ^b   Kostenis, Evi ^a  

^a 7TM Pharma A S   (Denmark)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 ETHOXYPHENYL) 5 METHOXY 2 METHYLINDOLE 3 CARBOXYLIC ACID; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELL; GUANINE NUCLEOTIDE BINDING PROTEIN; INDOLE DERIVATIVE; INDOMETACIN; N ALPHA TOSYLTRYPTOPHAN; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; RAMATROBAN; RETINA S ANTIGEN; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL SURFACE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; WHOLE CELL;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; HUMANS; INDOLES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RENILLA; SIGNAL TRANSDUCTION;

EID: 23044460265     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.010520     Document Type: Article

References (38)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Avlani V, May LT, Sexton PM, and Christopoulos A (2004) Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 308:1062-1072.
3. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
4. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
5. Black JW, Duncan WA, Durant CJ, Ganellin CR, and Parsons EM (1972) Definition and antagonism of histamine H2 receptors. Nature (Lond) 236:385-390.
6. Bohm E, Sturm GJ, Weiglhofer I, Sandig H, Shichijo M, McNamee A, Pease JE, Kollroser M, Peskar BA, and Heinemann A (2004) 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptorhomologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 279:7663-7670.
7. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
8. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
9. Figler H, Olsson RA, and Linden J (2003) Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Mol Pharmacol 64:1557-1564.
10. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, and Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144.
11. Gao ZG, Kim SG, Soltysiak KA, Melman N, IJzerman AP, and Jacobson KA (2002) Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol 62:81-89.
12. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary HD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105.
13. Gervais FG, Morello J-P, Beaulieu C, Sawyer N, Denis D, Greig G, Malebranche AD, and O'Neill GP (2005) Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol 67:1834-1839.
14. Gurevich VV and Gurevich EV (2004) The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 25:105-111.
15. Hata AN, Lybrand TP, Marnett LJ, and Breyer RM (2005) Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 67:640-647.
16. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, and Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168:981-985.
17. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seventransmembrane receptor CRTH2. J Exp Med 193:255-261.
18. Jensen AA and Spalding TA (2004) Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 21:407-420.
19. Kenakin T (2001) Inverse, protean and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
20. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
21. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
22. Kostenis E (2001) Is Galpha16 the optimal tool for fishing ligands of orphan Gprotein-coupled receptors? Trends Pharmacol Sci 22:560-564.
23. Kostenis E, Martini L, Ellis J, Waldhoer M, Heydorn A, Rosenkilde MM, Norregaard PK, Jorgensen R, Whistler JL, and Milligan G (2005) A highly conserved glycine within linker I and the extreme C terminus of G protein α subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity. J Pharmacol Exp Ther 313:78-87.
24. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283.
25. Kukkonen JP, Nasman J, and Akerman KE (2001) Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response. Trends Pharmacol Sci 22:616-622.
26. Lazareno S, Popham A, and Birdsall NJ (2002) Towards a high-affinity allosteric enhancer at muscarinic M1 receptors. J Mol Neurosci 19:123-127.
27. Luttrell LM and Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465.
28. Milligan G and White JH (2001) Protein-protein interactions at G protein-coupled receptors. Trends Pharmacol Sci 22:513-518.
29. Mohr M, Heller E, Ataie A, Mohr K, and Holzgrabe U (2004) Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84. J Med Chem 47:3324-3327.
30. Muth M, Bender W, Scharfenstein O, Holzgrabe U, Balatkova E, Trankle C, and Mohr K (2003) Systematic development of high affinity bis(ammonio)alkane- type allosteric enhancers of muscarinic ligand binding. J Med Chem 46:1031-1040.
31. Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, and Gervais FG (2002) Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 137:1163-1172.
32. 2-induced eosinophilia in rats. J Pharmacol Exp Ther 307:518-525.
33. Soudijn W, van Wijngaarden I, and IJzerman AP (2002) Allosteric modulation of G protein-coupled receptors. Curr Opin Drug Discov Devel 5:749-755.
34. 2-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem 277:26012-26020.
35. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, and Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY U3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305:347-352.
36. Terrillon S and Bouvier M (2004) Roles of G protein-coupled receptor dimerization. EMBO Rep 5:30-34.
37. Ulven T and Kostenis E (2005) Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem 48:897-900.
38. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.